Andrew Guggenhime, M.B.A.

Andrew Guggenhime, M.B.A.

Chair of the BoardatVaxcyte· In proxies 2021–2025

Pay in FY2024+230% from the year before · Vaxcyte stock +30.4% the same year

Andrew Guggenhime, M.B.A. was paid $17.9M in FY2024 (Dec), up 230%. Vaxcyte stock rose 30.4% that year.

Pay$100 in the stock at the end of FY20 → $308
Pay is from the Summary Compensation Table of each Vaxcyte proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Caribou BiosciencesPublic company · 3 yr
    • Chair of the Board2023 – Present · 3 yrNo stock prices for these years
  2. VaxcytePublic company · 5 yr
    • President and Chief Financial Officer2021 – Present · 5 yrStock in role +120%
  3. Sling TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  4. Metacrine, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Caribou BiosciencesChair · 2 yr on the boardIndependentAudit (Chair), Compensation (Chair)—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?